DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
H•••••••• I••
Drug Discovery & Developmentgroup grade Aoff every schedule since Jun 30, 2025sponsor unattributed
Also written as: 2022; 3; 5; 5/3/2022; Equity
Nothing material in the last 200 days. No dated change on record yet.
Principal held
unknown
sum of BDC pieces, a lower bound
Fair value
$468,000
n/a on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
unstated
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2025
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2025, folded to one row per lender
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | equity equity A••••••••• D••• 5/3/2022, Series C••••• S•••• | Not disclosed | $468,000 12c |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2025
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Jun 30, 2024 | at least $20.8M | 99c | S+105 bp PIK 2.85% | May 1, 2027 | 1 |
Equity pieces beside the debt: equity ($468,000 fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2025 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2024 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2024 | 1 | $0 | $0 | n/a | 0 |
All 11 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2024 | 1 | $20.8M | $20.9M | 99c | 1 |
| Mar 31, 2024 | 1 | $20.7M | $20.7M | 99c | 1 |
| Dec 31, 2023 | 1 | $41.0M | $40.7M | 98c | 2 |
| Sep 30, 2023 | 1 | $20.4M | $19.8M | 97c | 1 |
| Jun 30, 2023 | 1 | $20.2M | $19.2M | 95c | 1 |
| Mar 31, 2023 | 1 | $12.2M | $11.5M | 94c | 1 |
| Dec 31, 2022 | 1 | $12.1M | $11.3M | 94c | 1 |
What changed
- Facility left every BDC scheduleJun 30, 2024
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- HILLEVAXderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it